The value of temozolomide in combination with radiotherapy during standard treatment for newly diagnosed glioblastoma

Journal of Neuro-Oncology

Volumn 112, Issue 2, 2013, Pages 277-283

  Park, Chul Kee ^a   Lee, Se Hoon ^a,b   Kim, Tae Min ^a,b   Choi, Seung Hong ^a   Park, Sung Hye ^a   Heo, Dae Seog ^a,b   Kim, Il Han ^a   Jung, Hee Won ^a  

^a Seoul National University Hospital   (South Korea)

^b Seoul National University   (South Korea)

Author keywords

Adjuvant; Concomitant; Glioblastoma; MGMT; Temozolomide

Indexed keywords

METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; TEMOZOLOMIDE; ALKYLATING AGENT; DACARBAZINE; DNA METHYLTRANSFERASE; DRUG DERIVATIVE; MGMT PROTEIN, HUMAN; POLYDEOXYRIBONUCLEOTIDE SYNTHASE; TUMOR SUPPRESSOR PROTEIN;

ADULT; AGED; ARTICLE; BRAIN SURGERY; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; DNA METHYLATION; FEMALE; FOLLOW UP; GENE; GLIOBLASTOMA; HUMAN; MAJOR CLINICAL STUDY; MALE; MGMT GENE; MULTIPLE CYCLE TREATMENT; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; PROMOTER REGION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RETROSPECTIVE STUDY; ADJUVANT CHEMOTHERAPY; BRAIN TUMOR; CANCER STAGING; CHEMORADIOTHERAPY; COMPARATIVE STUDY; DISEASE COURSE; GENETICS; MIDDLE AGED; MORTALITY; MULTICENTER STUDY (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROGNOSIS; PROSPECTIVE STUDY; SURVIVAL RATE; TUMOR RECURRENCE;

ADULT; AGED; ANTINEOPLASTIC AGENTS, ALKYLATING; BRAIN NEOPLASMS; CHEMORADIOTHERAPY; CHEMOTHERAPY, ADJUVANT; CLINICAL TRIALS, PHASE III AS TOPIC; DACARBAZINE; DISEASE PROGRESSION; DNA METHYLATION; DNA MODIFICATION METHYLASES; DNA REPAIR ENZYMES; FEMALE; FOLLOW-UP STUDIES; GLIOBLASTOMA; HUMANS; MALE; MIDDLE AGED; MULTICENTER STUDIES AS TOPIC; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROGNOSIS; PROMOTER REGIONS, GENETIC; PROSPECTIVE STUDIES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SURVIVAL RATE; TUMOR SUPPRESSOR PROTEINS;

EID: 84883749602     PISSN: 0167594X     EISSN: 15737373     Source Type: Journal    
DOI: 10.1007/s11060-013-1060-3     Document Type: Article

References (17)

1. Stupp R, Mason WP, van den Bent MJ et al (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352:987-996 (Pubitemid 40349501)
2. Cohen MH, Johnson JR, Pazdur R (2005) Food and Drug Administration Drug approval summary: temozolomide plus radiation therapy for the treatment of newly diagnosed glioblastoma multiforme. Clin Cancer Res 11:6767-6771 (Pubitemid 41428729)
3. Athanassiou H, Synodinou M, Maragoudakis E et al (2005) Randomized phase II study of temozolomide and radiotherapy compared with radiotherapy alone in newly diagnosed glioblastoma multiforme. J Clin Oncol: Off J Am Soc Clin Oncol 23:2372-2377 (Pubitemid 46218731)
4. Lanzetta G, Campanella C, Rozzi A et al (2003) Temozolomide in radio-chemotherapy combined treatment for newly-diagnosed glioblastoma multiforme: phase II clinical trial. Anticancer res 23:5159-5164 (Pubitemid 38182140)
5. Stupp R, Dietrich PY, Ostermann Kraljevic S et al (2002) Promising survival for patients with newly diagnosed glioblastoma multiforme treated with concomitant radiation plus temozolomide followed by adjuvant temozolomide. J Clin Oncol: Off J Am Soc Clin Oncol 20:1375-1382 (Pubitemid 34177445)
6. Stupp R, Hegi ME, Mason WP et al (2009) Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 10:459-466
7. Sher DJ, Henson JW, Avutu B et al (2008) The added value of concurrently administered temozolomide versus adjuvant temozolomide alone in newly diagnosed glioblastoma. J Neurooncol 88:43-50
8. Kim IH, Park CK, Heo DS et al (2011) Radiotherapy followed by adjuvant temozolomide with or without neoadjuvant ACNU-CDDP chemotherapy in newly diagnosed glioblastomas: a prospective randomized controlled multicenter phase III trial. J Neurooncol 103:595-602
9. Macdonald DR, Cascino TL, Schold SC Jr et al (1990) Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol: Off J Am Soc Clin Oncol 8:1277-1280 (Pubitemid 20195640)
10. Wen PY, Macdonald DR, Reardon DA et al (2010) Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J Clin Oncol: Off J Am Soc Clin Oncol 28:1963-1972
11. Park CK, Kim J, Yim SY et al (2011) Usefulness of MS-MLPA for detection of MGMT promoter methylation in the evaluation of pseudoprogression in glioblastoma patients. Neuro-oncology 13:195-202
12. Hegi ME, Diserens AC, Gorlia T et al (2005) MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 352:997-1003 (Pubitemid 40349502)
13. Chakravarti A, Erkkinen MG, Nestler U et al (2006) Temozolomide-mediated radiation enhancement in glioblastoma: a report on underlying mechanisms. Clin Cancer Res 12:4738-4746 (Pubitemid 44297828)
14. Koukourakis GV, Kouloulias V, Zacharias G et al (2009) Temozolomide with radiation therapy in high grade brain gliomas: pharmaceuticals considerations and efficacy; a review article. Molecules 14:1561-1577
15. Kil WJ, Cerna D, Burgan WE et al (2008) In vitro and in vivo radiosensitization induced by the DNA methylating agent temozolomide. Clin Cancer Res 14:931-938 (Pubitemid 351231178)
16. Wedge SR, Porteous JK, Glaser MG et al (1997) In vitro evaluation of temozolomide combined with X-irradiation. Anticancer Drugs 8:92-97 (Pubitemid 27064756)
17. Hofer S, Lassman AB (2010) Molecular markers in gliomas: impact for the clinician. Target oncol 5:201-210